Report overview
Pericarditis is the inflammation of the pericardium. Pericardium is two thin layers of a sac like structure of tissues that surrounds the heart. The pericardium holds the heart in place and helps it work. It is a small amount of fluid that keeps both the layers separated from each other so that there is no friction between the layers. Pericarditis often causes chest pain and other symptoms too. The harsh chest pain associated with pericardium occurs when the layers of the pericardium rub against each other. Pericarditis usually begins suddenly but does not last for long.When symptoms related to pericarditis develops more gradually or persists, it is considered as chronic pericarditis. Most cases of pericarditis are mild and usually improve on their own. The common symptoms related to pericarditis include cough; leg or abdominal swelling; low-grade fever; heart palpitations; shortness of breath when reclining; an overall sense of weakness, feeling sick or fatigue; and sharp, piercing chest pain. Pericarditis can be diagnosed with the help of electrocardiogram results, echocardiogram, physical examination, cardiac MRI, and reported symptoms.
This report aims to provide a comprehensive presentation of the global market for Pericarditis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pericarditis Drugs. This report contains market size and forecasts of Pericarditis Drugs in global, including the following market information:
Global Pericarditis Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Pericarditis Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
By Drug Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Pericarditis Drugs include Pfizer Inc, Sanofi, Novartis, Bayer, AstraZeneca, Takeda Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Ltd, Merck & Co., Inc and Abbive(Allergan), etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Pericarditis Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pericarditis Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Pericarditis Drugs Market Segment Percentages, by Type, 2022 (%)
By Drug
Nonsteroidal Anti-Inflammatory Agents (NSAIDs)
Colchicine
Steroids
Antibiotics
Others
By Route of Administration
Intravenous
Oral
Others
By Disease
Acute Pericarditis
Chronic Pericarditis
Recurrent Pericarditis
Idiopathic Pericarditis
Global Pericarditis Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Pericarditis Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Pericarditis Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Pericarditis Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pericarditis Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Pericarditis Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc
Sanofi
Novartis
Bayer
AstraZeneca
Takeda Pharmaceuticals Industries Ltd
Teva Pharmaceutical Industries Ltd
Merck & Co., Inc
Abbive(Allergan)
Hikma Pharmaceuticals PLC
Avion Pharmaceuticals LLC
Dr. Reddy?s Laboratories Ltd
Viatris
Amneal Pharmaceuticals LLC
Sun Pharmaceuticals Industries Ltd
Lupin
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pericarditis Drugs, market overview.
Chapter 2: Global Pericarditis Drugs market size in revenue.
Chapter 3: Detailed analysis of Pericarditis Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pericarditis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
